Suppr超能文献

Sex and age differences in the pharmacokinetics of alosetron.

作者信息

Koch K M, Palmer J L, Noordin N, Tomlinson J J, Baidoo C

机构信息

Clinical Pharmacology, GlaxoSmithKline, North Carolina, USA.

出版信息

Br J Clin Pharmacol. 2002 Mar;53(3):238-42. doi: 10.1046/j.0306-5251.2001.01565.x.

Abstract

AIMS

To determine the effects of sex and age on the pharmacokinetics of alosetron.

METHODS

Single oral and intravenous 2 mg doses of alosetron were administered on separate occasions to 48 healthy, young and elderly, males and females. Serum was sampled for 12 h post-dose to measure alosetron concentrations.

RESULTS

Serum concentrations of alosetron were higher in females than in males, resulting from a sex difference in clearance by metabolism. Mean clearance values were 504 vs 677 ml min(-1) in young females vs males (mean ratio 0.75), and 461 vs 670 ml min(-1) in elderly females vs males (mean ratio 0.69). The sex difference in alosetron pharmacokinetics achieved statistical significance in the elderly, but not in the young. Irrespective of sex, alosetron clearance was increased by smoking. Serum concentrations tended to be higher in the elderly, although the effect of age was generally not significant. Volume of distribution was smaller in females (approximately 63 l) compared with males (approximately 84 l), regardless of age or the sex difference in body weight.

CONCLUSIONS

A significant difference in clearance by metabolism of alosetron between the sexes, and possibly between the young and elderly was observed.

摘要

相似文献

1
Sex and age differences in the pharmacokinetics of alosetron.
Br J Clin Pharmacol. 2002 Mar;53(3):238-42. doi: 10.1046/j.0306-5251.2001.01565.x.
2
Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.
Aliment Pharmacol Ther. 2004 Jul 15;20(2):223-30. doi: 10.1111/j.1365-2036.2004.02031.x.
3
Effect of alosetron on theophylline pharmacokinetics.
Br J Clin Pharmacol. 2001 Nov;52(5):596-600. doi: 10.1046/j.0306-5251.2001.01477.x.
4
Determination of alosetron in human plasma or serum by high-performance liquid chromatography with robotic sample preparation.
J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):261-7. doi: 10.1016/0378-4347(95)00491-2.
5
Effect of alosetron on the pharmacokinetics of fluoxetine.
J Clin Pharmacol. 2001 Apr;41(4):455-8. doi: 10.1177/00912700122010177.
6
Effect of alosetron on the pharmacokinetics of alprazolam.
J Clin Pharmacol. 2001 Apr;41(4):452-4. doi: 10.1177/00912700122010168.
8
Effect of alosetron (a new 5-HT3 receptor antagonist) on the pharmacokinetics of haloperidol in schizophrenic patients.
J Clin Pharmacol. 1995 Feb;35(2):202-7. doi: 10.1002/j.1552-4604.1995.tb05012.x.
9
Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.
Pain. 2006 Dec 15;126(1-3):54-63. doi: 10.1016/j.pain.2006.06.014. Epub 2006 Jul 17.

引用本文的文献

3
Sex-Bias in Irritable Bowel Syndrome: Linking Steroids to the Gut-Brain Axis.
Front Endocrinol (Lausanne). 2021 May 19;12:684096. doi: 10.3389/fendo.2021.684096. eCollection 2021.
4
Population pharmacokinetics of ramosetron.
J Pharmacokinet Pharmacodyn. 2016 Feb;43(1):73-83. doi: 10.1007/s10928-015-9455-8. Epub 2015 Nov 11.
5
The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Therap Adv Gastroenterol. 2015 May;8(3):136-42. doi: 10.1177/1756283X15572580.
6
Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle.
Gastroenterol Rep (Oxf). 2015 Aug;3(3):185-93. doi: 10.1093/gastro/gov010. Epub 2015 Mar 18.
8
Sex hormones in the modulation of irritable bowel syndrome.
World J Gastroenterol. 2014 Mar 14;20(10):2433-48. doi: 10.3748/wjg.v20.i10.2433.
9
In vivo effects of Faizol Ubat Batuk, a herbal product on aminopyrine metabolism in rat hepatocytes.
Libyan J Med. 2011;6. doi: 10.3402/ljm.v6i0.5439. Epub 2011 Sep 28.
10
Stress-related alterations of visceral sensation: animal models for irritable bowel syndrome study.
J Neurogastroenterol Motil. 2011 Jul;17(3):213-34. doi: 10.5056/jnm.2011.17.3.213. Epub 2011 Jul 13.

本文引用的文献

1
2
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Clin Pharmacokinet. 1999 Sep;37(3):177-93. doi: 10.2165/00003088-199937030-00001.
3
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist.
Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59. doi: 10.1046/j.1365-2036.1999.00610.x.
4
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Clin Pharmacol Ther. 1998 Aug;64(2):133-43. doi: 10.1016/S0009-9236(98)90146-1.
5
A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.
J Clin Psychopharmacol. 1996 Feb;16(1):19-25. doi: 10.1097/00004714-199602000-00004.
6
Determination of alosetron in human plasma or serum by high-performance liquid chromatography with robotic sample preparation.
J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):261-7. doi: 10.1016/0378-4347(95)00491-2.
7
Gender effects in pharmacokinetics and pharmacodynamics.
Drugs. 1995 Aug;50(2):222-39. doi: 10.2165/00003495-199550020-00003.
8
Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.
Clin Pharmacol Ther. 1993 Jun;53(6):691-5. doi: 10.1038/clpt.1993.91.
9
Effects of age and sex on piroxicam disposition.
Clin Pharmacol Ther. 1985 Jan;37(1):13-8. doi: 10.1038/clpt.1985.4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验